Ardelyx (ARDX) Competitors $4.48 +0.13 (+2.99%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$4.51 +0.03 (+0.67%) As of 09:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. MRUS, ACLX, ACAD, SWTX, RARE, AAPG, PTGX, RNA, SRRK, and MLTXShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), Avidity Biosciences (RNA), Scholar Rock (SRRK), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Merus Arcellx ACADIA Pharmaceuticals SpringWorks Therapeutics Ultragenyx Pharmaceutical Ascentage Pharma Group International Protagonist Therapeutics Avidity Biosciences Scholar Rock MoonLake Immunotherapeutics Merus (NASDAQ:MRUS) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Which has stronger earnings & valuation, MRUS or ARDX? Ardelyx has higher revenue and earnings than Merus. Ardelyx is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$36.13M100.24-$215.33M-$4.08-12.83Ardelyx$361.71M2.96-$39.14M-$0.22-20.36 Is MRUS or ARDX more profitable? Ardelyx has a net margin of -14.86% compared to Merus' net margin of -506.73%. Ardelyx's return on equity of -34.45% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Merus-506.73% -35.99% -29.83% Ardelyx -14.86%-34.45%-13.81% Which has more risk and volatility, MRUS or ARDX? Merus has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Ardelyx has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Does the media favor MRUS or ARDX? In the previous week, Ardelyx had 5 more articles in the media than Merus. MarketBeat recorded 9 mentions for Ardelyx and 4 mentions for Merus. Merus' average media sentiment score of 1.14 beat Ardelyx's score of 0.61 indicating that Merus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts prefer MRUS or ARDX? Merus currently has a consensus target price of $84.64, suggesting a potential upside of 61.74%. Ardelyx has a consensus target price of $10.89, suggesting a potential upside of 143.06%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of MRUS or ARDX? 96.1% of Merus shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 4.6% of Merus shares are held by insiders. Comparatively, 4.8% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryArdelyx beats Merus on 9 of the 17 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$2.68B$5.50B$8.94BDividend YieldN/A1.79%5.25%4.04%P/E Ratio-20.368.9826.9720.11Price / Sales2.96714.59426.02119.76Price / CashN/A159.8036.8257.86Price / Book6.144.517.985.56Net Income-$39.14M$31.26M$3.16B$248.40M7 Day Performance6.92%3.57%2.36%4.67%1 Month Performance19.15%1.28%2.15%6.64%1 Year Performance-19.42%1.08%33.78%21.31% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.4362 of 5 stars$4.48+3.0%$10.89+143.1%-17.8%$1.07B$361.71M-20.3690MRUSMerus2.0988 of 5 stars$52.60-0.7%$84.64+60.9%-6.1%$3.64B$54.73M-12.8937News CoveragePositive NewsACLXArcellx2.3004 of 5 stars$65.85+0.8%$111.23+68.9%+19.3%$3.63B$107.94M-22.0280ACADACADIA Pharmaceuticals4.6769 of 5 stars$21.57-2.5%$27.88+29.2%+28.8%$3.61B$996.28M15.74510SWTXSpringWorks Therapeutics1.5425 of 5 stars$46.99+0.0%$52.57+11.9%N/A$3.54B$191.59M-13.78230RAREUltragenyx Pharmaceutical4.0685 of 5 stars$36.36-0.4%$87.00+139.3%-5.0%$3.44B$590.69M-6.181,294AAPGAscentage Pharma Group InternationalN/A$39.38-0.6%N/AN/A$3.43B$134.35M0.00600News CoveragePositive NewsPTGXProtagonist Therapeutics2.3405 of 5 stars$55.27-0.8%$66.10+19.6%+43.3%$3.43B$434.43M73.69120News CoverageRNAAvidity Biosciences2.4663 of 5 stars$28.40-2.2%$65.59+130.9%-24.3%$3.42B$10.90M-9.47190SRRKScholar Rock3.3139 of 5 stars$35.42-1.1%$42.67+20.5%+335.1%$3.36B$33.19M-14.00140MLTXMoonLake Immunotherapeutics2.1668 of 5 stars$47.20-0.7%$74.50+57.8%+7.4%$3.02BN/A-20.522News CoveragePositive News Related Companies and Tools Related Companies MRUS Competitors ACLX Competitors ACAD Competitors SWTX Competitors RARE Competitors AAPG Competitors PTGX Competitors RNA Competitors SRRK Competitors MLTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
